Market Overview

Bristol-Myers Squibb Says Orencia Approved by EU

Share:
Related BMY
Chardan Initiates Asterias Biotherapeutics At Buy On Potential Cell Therapy Competitiveness
Inovalon And Bristol-Myers Squibb Strike Deal To Focus On Real World Outcomes & Value-Based Contracting Initiatives

Bristol-Myers Squibb announced today that the European Commission has granted marketing authorisation for the subcutaneous formulation of ORENCIA ® (abatacept), in combination with methotrexate (MTX), for the treatment of adults with moderate to severe active rheumatoid arthritis (RA).

Posted-In: News FDA

 

Related Articles (BMY)

View Comments and Join the Discussion!